We therefore propose three possible downstream mediators of the PRMT5–KRAS crosstalk for the first time as a possible molecular mechanism for the greater efficacy of PRMT5 inhibition in KRAS mutant CRC when compared to KRAS WT CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.